-

Astepro® Allergy Partners with Meghann Fahy to Help Allergy Sufferers Conquer Allergies, Love & Spontaneity Fast

Astepro® Allergy starts working in 30 minutes so you can feel sexy fast this spring.

NEW YORK--(BUSINESS WIRE)--No one feels sexy when spring allergies hit. Introducing Astepro® Allergy – the only long-lasting nasal spray that starts working in 30 minutes, so allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.

As a longtime allergy sufferer herself, Meghann Fahy understands the daily woes of powering through the runny nose or nasal congestion from allergies, but not anymore. Astepro® and Meghann are working together to give allergy sufferers what they need to pursue passion this spring.

“Astepro wants to change the way allergy sufferers approach life with allergies by giving them the ability to find relief starting in 30 minutes and jump into whatever comes their way,” explains Catherine Vennat, General Manager, and Vice-President, US Marketing Allergy, Cough & Cold at Bayer. “About every 7 in 10 allergy sufferers say allergies make them feel less attractive or admit it’s affected their love life. The fast, steroid-free allergy relief lets you be ready anytime and that’s a little boost to your confidence when you need it.”

“I’ve been suffering from seasonal allergies for years and nothing makes me feel less sexy than compulsively sneezing,” said actress Meghann Fahy. “Astepro® Allergy provides relief when my allergies are at their worst, so I don’t have to hold back and can be my spontaneous self.”

Going beyond just seasonal allergy relief, the brand has created an ultra-limited-edition unisex eau de toilette, La Spontanéité. This ultimate dynamic duo aims to celebrate life’s spontaneously sexy moments this spring, bringing together Astepro’s 30 minutes allergy relief and a unisex eau de toilette so you’re ready for anything, anywhere.

To further encourage consumers to relieve their allergies and live spontaneously this spring, Astepro® is hosting the Feel Sexy Fast Sweepstakes, where fans will have the chance to win a limited edition Astepro® kit, including La Spontanéité and Astepro®, among other special prizes.

To enter, fans can follow @astepro_us on Instagram, tagging a friend and commenting a memory of when their allergies kept them from feeling sexy including #sweepstakes. The Astepro Feel Sexy Fast Sweepstakes launches on Thursday, April 20, 2023 at 10:00 a.m. ET and ends Monday, May 22, 2023 at 11:59 p.m. ET. No purchase necessary. Void where prohibited. Open to continental United States residents (excluding Alaska, Hawaii, the U.S. Territories and Puerto Rico) who 21 years of age or older at time of entry. For official rules, visit: https://www.asteproallergy.com/feel-sexy-fast-giveaway-rules.

Astepro® Allergy, with the steroid-free active ingredient Azelastine hydrochloride, is the first and only over-the-counter antihistamine nasal spray for indoor and outdoor allergies that begins working in 30 minutes, providing allergy sufferers with ready anytime, fast relief.

Astepro® Allergy is available nationwide at mass retail locations. For more information, please visit https://www.asteproallergy.com/

Survey was conducted via Pollfish in September 2022 among 200 allergy sufferers that suffer from allergies over 100 days per year.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. For more information, go to www.bayer.com.

Contacts

Danielle K. Goonan
danielle.goonan@bayer.com

Bayer


Release Versions

Contacts

Danielle K. Goonan
danielle.goonan@bayer.com

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom